FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:551-554 August 24, 2000 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Gastric carcinoid tumors are rare tumors that originate from gastric enterochromaffin-like cells in the oxyntic mucosa.¹ There are three types of gastric carcinoid tumors: type I is associated with chronic atrophic gastritis, type II develops in patients with combined multiple endocrine neoplasia type 1 and the Zollinger–Ellison syndrome, and type III is sporadic.¹ Although the pathogenesis of these tumors is not completely understood, hypergastrinemia has an important role in the development of types I and II.² The multiple endocrine neoplasia type 1 gene locus may be involved in type II gastric carcinoid tumors.^3,4

All three types are usually removed surgically . . . [Full Text of this Article]

Case Reports

Patient 1

Patient 2

Patient 3

Methods

Results

Discussion

Source Information

From the Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy.

Address reprint requests to Dr. Gullo at the Department of Internal Medicine and Gastroenterology, S. Orsola Hospital, Via Massarenti, 9, I-40138 Bologna, Italy.

References

This article has been cited by other articles:

• Grozinsky-Glasberg, S., Kaltsas, G., Gur, C., Gal, E., Thomas, D., Fichman, S., Alexandraki, K., Barak, D., Glaser, B., Shimon, I., Gross, D. J (2008). Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 159: 475-482 [Abstract] [Full Text]  
• Grozinsky-Glasberg, S., Shimon, I., Korbonits, M., Grossman, A. B (2008). Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 15: 701-720 [Abstract] [Full Text]  
• Campana, D, Nori, F, Pezzilli, R, Piscitelli, L, Santini, D, Brocchi, E, Corinaldesi, R, Tomassetti, P (2008). Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 15: 337-342 [Abstract] [Full Text]  
• Schott, M., Sagert, C., Willenberg, H. S., Schinner, S., Ramp, U., Varro, A., Raffel, A., Eisenberger, C., Zacharowski, K., Perren, A., Scherbaum, W. A. (2007). Carcinogenic Hypergastrinemia: Signet-Ring Cell Carcinoma in a Patient with Multiple Endocrine Neoplasia Type 1 with Zollinger-Ellison's Syndrome. J. Clin. Endocrinol. Metab. 92: 3378-3382 [Abstract] [Full Text]  
• Marx, S. J., Simonds, W. F. (2005). Hereditary Hormone Excess: Genes, Molecular Pathways, and Syndromes. Endocr. Rev. 26: 615-661 [Abstract] [Full Text]  
• Kaltsas, G. A., Besser, G. M., Grossman, A. B. (2004). The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors. Endocr. Rev. 25: 458-511 [Abstract] [Full Text]